NCT Number: NCT00154362
The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.
Conduct disorder is a group of psychiatric symptoms that can include clinical characteristics of impulsivity and aggressive behavior. This study will investigate the efficacy a safety of oxcarbazepine in the treatment of adolescents with conduct disorder.
Looking for future studies?
Notify MeKey information
Conditions
Age range
6 year–16 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- History of conduct disorder, oppositional defiant disorder, and disruptive behavior disorder not otherwise specified
- Score >8 on the Impulsivity Rating Scale
Exclusion criteria
- Other serious medical or psychiatric conditions excluding conduct disorder, oppositional defiant disorder, and disruptive behavior disorder not otherwise specified
- Treatment with antiepileptic medications
Other protocol-defined inclusion/exclusion criteria may apply.
Treatment and study plan
Primary outcomes
-
Percentage reduction on Impulsivity Rating Scale (IRS)
Secondary outcomes
-
Percent reduction in the Modified Overt Aggression Scale (MOAS)
Sponsors and collaborators
Lead sponsor
Novartis
Industry
Registry information
Official study title
A Multi-center, Randomized, Double-blind, Cross-over, Placebo-controlled Clinical Trial to Evaluate Efficacy and Safety of Oxcarbazepine p.o. (300-1200 mg/Day) as Adjuvant Therapy for Impulsivity and Aggressive Behavior in Conduct Disorders in Adolescents
Important dates
- Study start
- 2003
- Primary completion
- 2004
- Study completion
- 2004
- First posted
- Sep 12, 2005
- Registry last updated
- Nov 24, 2011
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Impact VR: An Emotion Recognition and Regulation Training Program for Youth With CD
NCT06301516
Attention Deficit and Disruptive Behavior Disorders, Callous-Unemotional Traits
Richmond, Virginia, United States
View Trial DetailsThe Effectiveness of Forensic Outpatient Systemic Therapy: a Multiple Case Experimental Design
NCT06032520
Aberrant Motor Behavior in Dementia, Aggression
Utrecht, Netherlands
View Trial DetailsIntegrated Smart Speaker Promoting Positive Parenting Among Caregivers of Youth With Challenging Behaviors
NCT05535387
Attention Deficit and Disruptive Behavior Disorders, Conduct Disorder
Springfield, Oregon, United States
View Trial DetailsIntervening Early: Key Adolescent Outcomes
NCT04168684
Anxiety Disorders, Attention Deficit and Disruptive Behavior Disorders
Newark, Delaware, United States
View Trial Details